Mounjaro Beats Wegovy in Head-to-Head Weight-Loss Trial as Blockbuster Drug Reshapes Obesity in the US and UK
Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, produced substantially more weight loss than Novo Nordisk's Wegovy in the first head-to-head trial of the two leading obesity drugs. Those results helped tirzepatide overtake Merck's cancer drug Keytruda as the world's best-selling medicine. At the same time, surveys in the United States and Britain suggest the drugs are changing obesity rates, shopping habits and what the medicines are mainly used for.
In the SURMOUNT-5 trial, published in the New England Journal of Medicine, adults with obesity who took tirzepatide lost an average of 20.2% of their body weight over 72 weeks, about 50 pounds. Those on semaglutide, the active ingredient in Wegovy, lost an average of 13.7%, about 33 pounds.
The Lilly-sponsored phase 3b study enrolled 751 adults with obesity but without type 2 diabetes at 32 sites in the United States and Puerto Rico. Participants received the maximum tolerated doses of each drug along with diet and exercise counseling.
About 32% of people on tirzepatide lost at least a quarter of their body weight, compared with 16% on semaglutide. Tirzepatide also produced a greater reduction in waist circumference. Side effects were similar in both groups: about 44% of each reported nausea and about 25% reported abdominal pain.
"Doctors, insurance companies and patients are always asking, 'which drug is more effective?'" said Dr. Louis Aronne of Weill Cornell Medicine and NewYork-Presbyterian, who led the study. "This study allowed us to do a direct comparison."
Researchers believe the difference comes from how the drugs work. Semaglutide mimics a single gut hormone,........
